FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 296:481-485 March 3, 1977 Number 9 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

The increased use of drugs (and the concurrent increased risks of drug-induced illness) require definition of relevant research areas and strategy. For established marketed drugs, research needs depend on the magnitudes of risk of an illness from a drug and the base-line risk. With the drug risk high and the base-line risk low, the problem surfaces in premarketing studies or through the epidemic that develops after marketing. If the drug adds slightly to a high base-line risk, the effect is undetectable. When both risks are low, adverse effects can be discovered by chance, but systematic case-referent studies can speed discovery. If both risks are high, clinical trials and nonexperimental studies may be used. With both risks intermediate, systematic evaluations, especially case-referent studies are needed. Newly marketed drugs should be routinely evaluated through compulsory registration and follow-up study of the earliest users.

This article has been cited by other articles:

• Kilbridge, P. M., Campbell, U. C., Cozart, H. B., Mojarrad, M. G. (2006). Automated Surveillance for Adverse Drug Events at a Community Hospital and an Academic Medical Center. J. Am. Med. Inform. Assoc. 13: 372-377 [Abstract] [Full Text]  
• Papanikolaou, P. N., Christidi, G. D., Ioannidis, J. P.A. (2006). Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 174: 635-641 [Abstract] [Full Text]  
• Ferner, R E (2005). The influence of big pharma. BMJ 330: 855-856 [Full Text]  
• Vandenbroucke, J. P (2004). Benefits and harms of drug treatments. BMJ 329: 2-3 [Full Text]  
• Vandenbroucke, J. P (2003). Balancing benefits and harms in health care: Observational data on harm should complement systematic reviews of benefit. BMJ 327: 750-750 [Full Text]  
• Buekens, P. (2001). Invited Commentary: Rare Side Effects of Obstetric Interventions: Are Observational Studies Good Enough?. Am J Epidemiol 153: 108-109 [Full Text]  
• Moore, T. J., Psaty, B. M., Furberg, C. D. (1998). Time to Act on Drug Safety. JAMA 279: 1571-1573 [Full Text]